| pubmed-article:15838670 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15838670 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15838670 | lifeskim:mentions | umls-concept:C0039730 | lld:lifeskim |
| pubmed-article:15838670 | lifeskim:mentions | umls-concept:C0020402 | lld:lifeskim |
| pubmed-article:15838670 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:15838670 | pubmed:dateCreated | 2005-6-7 | lld:pubmed |
| pubmed-article:15838670 | pubmed:abstractText | Pharmacological agents such as hydroxyurea (HU) have been known to cause induction of fetal hemoglobin and possibly may alleviate the symptoms in thalassemia intermedia patients. Thirty-seven patients with beta-thalassemia intermedia were enrolled to assess response to HU therapy. Major response was defined as transfusion independence or hemoglobin rise of more than 20 g/l and minor response as rise in hemoglobin of 10-20 g/l or reduction in transfusion frequency by 50%. The median age was 10 years (range: 4-50 years) and median follow-up was 12 months (range: 4-36 months). Twenty-six patients (70.2%) showed response to HU therapy. Seventeen patients (45.9%) were major responders, and nine patients (24.3%) showed minor response. There was no correlation of response with beta-thalassemia mutation or XmnI polymorphism; however, the presence of alpha(3.7) deletion was associated with major response in three patients. Mean fetal hemoglobin (HbF) levels rose on HU therapy. Older age, low baseline F cell percent, and low baseline HbF levels (below 10%) were predictors of poor response. Response was evident within 1 month of starting HU therapy in the majority of responders. Thus, a short trial of HU therapy can predict durable response. | lld:pubmed |
| pubmed-article:15838670 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15838670 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15838670 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15838670 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15838670 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15838670 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15838670 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15838670 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:15838670 | pubmed:issn | 0939-5555 | lld:pubmed |
| pubmed-article:15838670 | pubmed:author | pubmed-author:ChoudhryV PVP | lld:pubmed |
| pubmed-article:15838670 | pubmed:author | pubmed-author:TyagiSS | lld:pubmed |
| pubmed-article:15838670 | pubmed:author | pubmed-author:MahapatraMM | lld:pubmed |
| pubmed-article:15838670 | pubmed:author | pubmed-author:SaxenaRenuR | lld:pubmed |
| pubmed-article:15838670 | pubmed:author | pubmed-author:DixitAshishA | lld:pubmed |
| pubmed-article:15838670 | pubmed:author | pubmed-author:KabraMadhulik... | lld:pubmed |
| pubmed-article:15838670 | pubmed:author | pubmed-author:ChatterjeeT... | lld:pubmed |
| pubmed-article:15838670 | pubmed:author | pubmed-author:MishraPravasP | lld:pubmed |
| pubmed-article:15838670 | pubmed:author | pubmed-author:ChoudhryDharm... | lld:pubmed |
| pubmed-article:15838670 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15838670 | pubmed:volume | 84 | lld:pubmed |
| pubmed-article:15838670 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15838670 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15838670 | pubmed:pagination | 441-6 | lld:pubmed |
| pubmed-article:15838670 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:meshHeading | pubmed-meshheading:15838670... | lld:pubmed |
| pubmed-article:15838670 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15838670 | pubmed:articleTitle | Hydroxyurea in thalassemia intermedia--a promising therapy. | lld:pubmed |
| pubmed-article:15838670 | pubmed:affiliation | Department of Haematology, All India Institute of Medical Sciences, New Delhi, India. | lld:pubmed |
| pubmed-article:15838670 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15838670 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15838670 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15838670 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15838670 | lld:pubmed |
